View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	May 01, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Trading Symbol	FLGT
Entity Registrant Name	FULGENT GENETICS, INC.
Entity Central Index Key	0001674930
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		21,697,884
Entity File Number	001-37894
Entity Tax Identification Number	81-2621304
Entity Address, Address Line One	4978 Santa Anita Avenue
Entity Address, Address Line Two	Suite 205
Entity Address, City or Town	Temple City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91780
City Area Code	626
Local Phone Number	350-0537
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 9,302,000	$ 11,965,000
Marketable securities	18,028,000	16,304,000
Trade accounts receivable, net of allowance for doubtful accounts of $862 and $751, as of March 31, 2020 and December 31, 2019, respectively	6,371,000	6,555,000
Other current assets	3,324,000	2,255,000
Total current assets	37,025,000	37,079,000
Marketable securities, long-term	43,294,000	41,947,000
Equity method investments	623,000	872,000
Fixed assets, net	5,698,000	5,974,000
Operating lease right-of-use asset	2,525,000	2,633,000
Other long-term assets	160,000	251,000
Total assets	89,325,000	88,756,000
Current liabilities
Accounts payable	2,855,000	1,581,000
Accrued liabilities	2,024,000	1,333,000
Income tax payable	56,000	24,000
Contract liabilities	444,000	365,000
Operating lease liabilities, short-term	431,000	420,000
Total current liabilities	5,810,000	3,723,000
Operating lease liabilities, long-term	2,143,000	2,256,000
Total liabilities	7,953,000	5,979,000
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value per share, 50,000 shares authorized, 21,672 and 21,483 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	2,000	2,000
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding at March 31, 2020 and December 31, 2019
Additional paid-in capital	146,948,000	146,058,000
Accumulated other comprehensive income (loss)	(193,000)	146,000
Accumulated deficit	(65,385,000)	(63,429,000)
Total stockholders’ equity	81,372,000	82,777,000
Total liabilities and stockholders’ equity	$ 89,325,000	$ 88,756,000

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 862	$ 751
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	21,672,000	21,483,000
Common stock, shares outstanding	21,672,000	21,483,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenue	$ 7,753	$ 5,370
Cost of revenue	4,057	2,968
Gross profit	3,696	2,402
Operating expenses:
Research and development	1,978	1,424
Selling and marketing	1,597	1,272
General and administrative	2,035	1,529
Total operating expenses	5,610	4,225
Operating loss	(1,914)	(1,823)
Interest and other income, net	241	207
Loss before income taxes and equity loss in investee	(1,673)	(1,616)
Provision for income taxes	34	13
Loss before equity loss in investee	(1,707)	(1,629)
Equity loss in investee	(249)	(279)
Net loss	$ (1,956)	$ (1,908)
Net loss per common share:
Basic	$ (0.09)	$ (0.10)
Diluted	$ (0.09)	$ (0.10)
Weighted-average common shares:
Basic	21,566	18,228
Diluted	21,566	18,228

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (1,956)	$ (1,908)
Other comprehensive income (loss):
Foreign currency translation (loss) gain	(3)	15
Net unrealized (loss) gain on marketable securities, net of tax	(336)	115
Comprehensive loss	$ (2,295)	$ (1,778)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Stockholders' Equity	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2018	$ 51,152	$ 2	$ 114,203	$ (35)	$ (63,018)
Beginning Balance, Shares at Dec. 31, 2018		18,172,000
Equity-based compensation	583		583
Exercise of common stock options	4		4
Exercise of common stock options, Shares		9,000
Restricted stock awards, Shares		105,000
Other comprehensive gain (loss)	130			130
Net income (loss)	(1,908)				(1,908)
Ending Balance at Mar. 31, 2019	49,961	$ 2	114,790	95	(64,926)
Ending Balance, Shares at Mar. 31, 2019		18,286,000
Beginning Balance at Dec. 31, 2019	$ 82,777	$ 2	146,058	146	(63,429)
Beginning Balance, Shares at Dec. 31, 2019	21,483,000	21,483,000
Equity-based compensation	$ 924		924
Exercise of common stock options	12		12
Exercise of common stock options, Shares		33,000
Restricted stock awards, Shares		159,000
Repurchases of capital stock	(46)		(46)
Repurchases of capital stock, Shares		(3)
Other comprehensive gain (loss)	(339)			(339)
Net income (loss)	(1,956)				(1,956)
Ending Balance at Mar. 31, 2020	$ 81,372	$ 2	$ 146,948	$ (193)	$ (65,385)
Ending Balance, Shares at Mar. 31, 2020	21,672,000	21,672,000

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flow from operating activities:
Net loss	$ (1,956,000)	$ (1,908,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Equity-based compensation	924,000	583,000
Depreciation	569,000	535,000
Noncash lease expense	108,000	100,000
Amortization of premium of marketable securities	105,000	37,000
Provision for bad debt	121,000
Equity loss in investee	249,000	279,000
Other	(42,000)	(28,000)
Changes in operating assets and liabilities:
Accounts receivable	104,000	1,414,000
Other current and long-term assets	(924,000)	64,000
Accounts payable	1,907,000	79,000
Income tax payable	34,000
Accrued liabilities and other current liabilities	268,000	(7,000)
Operating lease liabilities	(101,000)	(93,000)
Net cash provided by operating activities	1,366,000	1,055,000
Cash flow from investing activities:
Purchases of fixed assets	(796,000)	(134,000)
Purchase of marketable securities	(7,992,000)	(5,988,000)
Maturities of marketable securities	4,926,000	3,600,000
Net cash used in investing activities	(3,862,000)	(2,522,000)
Cash flow from financing activities:
Proceeds from exercise of stock options	12,000	4,000
Payment of public offering costs	(130,000)
Repurchases of capital stock	(46,000)
Net cash (used in) provided by financing activities	(164,000)	4,000
Effect of exchange rate changes on cash and cash equivalents	(3,000)	15,000
Net decrease in cash and cash equivalents	(2,663,000)	(1,448,000)
Cash and cash equivalents at beginning of period	11,965,000	6,736,000
Cash and cash equivalents at end of period	9,302,000	5,288,000
Supplemental disclosures of non-cash investing and financing activities:
Fixed assets included in accounts payable	43,000	$ 45,000
Purchase of marketable securities in other current liabilities	500,000
Public offerings costs included in accounts payable	$ 1,000

Overview and Basis of Presentation

3 Months Ended

Mar. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Overview and Basis of Presentation

Note 1. Overview and Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These financial statements include the assets, liabilities, revenues and expenses of all wholly-owned subsidiaries and entities in which the Company has a controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. All significant intercompany accounts and transactions are eliminated from the accompanying condensed consolidated financial statements.

Nature of the Business

Fulgent Genetics, Inc., together with its subsidiaries (collectively referred to as the “Company,” unless otherwise noted or the context otherwise requires), is a technology company offering comprehensive genetic testing providing physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The Company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing, or NGS, with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. The Company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique genetic testing needs.

Unaudited Interim Financial Information

The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2019, which are included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2020 (the “2019 Annual Report”), and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company’s financial position and results of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or any other period. The accompanying Condensed Consolidated Balance Sheet as of December 31, 2019 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the disclosures required by U.S. GAAP. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the 2019 Annual Report, including the notes thereto.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

See the summary of the Company’s significant accounting policies set forth in the notes to its consolidated financial statements included in the 2019 Annual Report.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances, including but not limited to the potential impacts arising from the recent global pandemic related to the novel coronavirus (“COVID-19”). As the extent and duration of the impacts from COVID-19 remain unclear, the Company’s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates. Actual results could differ from these estimates.

On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) accounts receivable and allowances for doubtful accounts, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities and (v) equity method investments.

Foreign Currency Translation and Foreign Currency Transactions

The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in other comprehensive income (loss) in the accompanying Condensed Consolidated Statements of Stockholders’ Equity. Gains and losses from these translations were not significant in the first quarters of 2020 and 2019. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Losses from these remeasurements were $85,000 in the first quarter of 2020. Gain and losses from these remeasurements were not significant in the first quarter of 2019.

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included as operating lease right-of-use (“ROU”) assets, operating lease liabilities, short-term, and operating lease liabilities, long-term, on the Company’s Condensed Consolidated Balance Sheets.

ROU lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating ROU lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments since its leases do not provide an implicit rate. The ROU lease asset includes any base rent payments made and excludes lease incentives and variable operating expenses. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Concentration of Customers

In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. In the first quarter of 2020, after aggregating customers that are under common control or are affiliates, no customer contributed 10% or more of the Company’s revenue. In the in the first quarter of 2019, after aggregating customers that are under common control or are affiliates, two customers contributed 20% and 11% of the Company’s revenue. No customer comprised 10% or more of total accounts receivable as of March 31, 2020 and December 31, 2019.

Revenue from Contracts with Customers

Disaggregation of Revenue

The Company classifies its customers into three payor types, Clinical Institutional, Patients who pay directly or Clinical Insurance, as the Company believes this best depicts how the nature, amount, timing, and uncertainty of its revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the first quarters of 2020 and 2019.

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Genetic Testing Services by payor
Institutional	$	7,478	$	5,119
Patient		141		102
Insurance		134		149
Total Revenue	$	7,753	$	5,370

Contract Balances

Receivables from contracts with customers - As of March 31, 2020 and December 31, 2019, receivables from contracts with customers were approximately $6.4 million and $6.6 million, respectively, and are included within Trade accounts receivable on the Condensed Consolidated Balance Sheets.

Contracts assets and liabilities - As of March 31, 2020 and December 31, 2019, contract assets from contracts with customers were $150,000, associated with contract execution and included in other current assets in the accompanying Condensed Consolidated Balance Sheets. Contract liabilities are recorded when the Company receives payment prior to completing its obligation to transfer goods or services to a customer. The Company had $444,000 and $365,000 of contract liability as of March 31, 2020 and December 31, 2019, respectively. Revenues of $242,000 and $33,000 for the three months ended March 31, 2020 and 2019, respectively, related to contract liabilities at the beginning of the respective periods were recognized.

Transaction Price Allocated to Future Performance Obligations

The Company does not have material future obligations associated with genetic testing services that extend beyond one year.

Recent Accounting Pronouncements

The Company evaluates all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s condensed consolidated financial statements.

ASU No. 2016-13

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments. ASU No. 2016-13 replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The update is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those reporting periods for public business entities that meet the definition of an U.S. Securities and Exchange (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early application of the amendments is permitted. The Company does not expect the adoption of the new guidance under the standard to materially affect its financial position or results of operations and plans to adopt during the fiscal year 2023.

ASU No. 2018-15

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which provides new guidance on the accounting for implementation, set-up, and other upfront costs incurred in a hosted cloud computing arrangement. Under the new guidance, entities will apply the same criteria for capitalizing implementation costs as they would for an internal-use software license arrangement. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This ASU can be adopted prospectively to eligible costs incurred on or after the date of adoption or retrospectively. The adoption of this update did not have a material impact on the Company’s consolidated financial statements or disclosures.

ASU No. 2019-12

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740), which is intended to reduce the complexity of accounting standards while maintaining or enhancing the helpfulness of information provided to financial statement users. The amendment in this update simplifies the accounting for income taxes by removing some exceptions including the incremental approach for intraperiod tax allocation, the requirement to recognize a deferred tax liability for equity method investments, the ability not to recognize a deferred tax liability for a foreign subsidiary, and the general methodology for calculating income taxes in an interim period. Other changes include requiring entities to recognize franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate tax basis step-up in goodwill obtained in a transaction that is not a business combination, and reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, making minor codification improvements for income taxes related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method, and specifying that an entity is not required to allocate the consolidated current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements. This amendment is effective for public business entities beginning after December 15, 2020 with early adoption permitted. The Company has decided not to early adopt the amendments. The Company is currently evaluating the amendment and has not yet determined the impact on its consolidated financial statements.

Marketable Securities

3 Months Ended

Mar. 31, 2020

Investments Debt And Equity Securities [Abstract]

Marketable Securities

Note 3. Marketable Securities

The Company’s marketable securities consisted of the following:

	March 31, 2020
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	3,943		$	—	$	—		$	3,943
Corporate debt securities		18,048			31		(51	)		18,028
Less: Cash equivalents		(3,943	)		—		—			(3,943	)
Total short-term marketable securities		18,048			31		(51	)		18,028
Long-term
Corporate debt securities		42,484			125		(318	)		42,291
U.S. government agency securities		1,000			3		—			1,003
Total long-term marketable securities		43,484			128		(318	)		43,294
Total marketable securities	$	61,532		$	159	$	(369	)	$	61,322

	December 31, 2019
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	4,700		$	—	$	—		$	4,700
Corporate debt securities		17,962			43		(2	)		18,003
Less: Cash equivalents		(6,399	)		—		—			(6,399	)
Total short-term marketable securities		16,263			43		(2	)		16,304
Corporate debt securities		41,861			116		(30	)		41,947
Total long-term marketable securities		41,861			116		(30	)		41,947
Total marketable securities	$	58,124		$	159	$	(32	)	$	58,251

Management determined that the gross unrealized losses of $369,000 on the Company’s marketable securities as of March 31, 2020 were temporary in nature. Gross unrealized losses on the Company’s marketable securities were $32,000 as of December 31, 2019. The Company currently does not intend to sell these securities prior to maturity and does not consider these investments to be other-than-temporarily impaired as of March 31, 2020.

Fair Value Measurements

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 4. Fair Value Measurements

The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels:

Level 1:

Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.

Level 2:

Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Inputs are unobservable inputs for the asset or liability.

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

	March 31, 2020
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	60,319	$	—	$	60,319	$	—
U.S. government agency securities		1,003		—		1,003		—
Money market accounts		3,943		3,943		—		—
Total marketable securities	$	65,265	$	3,943	$	61,322	$	—

	December 31, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	59,950	$	—	$	59,950	$	—
Money market accounts		4,700		4,700		—		—
Total marketable securities and cash equivalents	$	64,650	$	4,700	$	59,950	$	—

The Company’s Level 1 assets include money market instruments and are valued based upon observable market prices. Level 2 assets consist of U.S. government agency securities and corporate debt securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. As of March 31, 2020, the Company had no investments that were measured using unobservable (Level 3) inputs.

There were no transfers between fair value measurement levels during the first quarter of 2020.

Gross unrealized gains or losses for cash equivalents and marketable securities as of March 31, 2020 were not material. As of March 31, 2020, there were no unrealized losses for securities in an unrealized loss position for more than 12 months. During the three months ended March 31, 2020, the Company did not recognize other-than-temporary impairment losses related to its marketable securities.

Fixed Assets

3 Months Ended

Mar. 31, 2020

Property Plant And Equipment [Abstract]

Fixed Assets

Note 5. Fixed Assets

Major classes of fixed assets consisted of the following:

		March 31,			December 31,
	Useful Lives	2020			2019
		(in thousands)
Computer hardware	3 Years	$	1,711		$	1,705
Computer software	3 Years		541			541
Medical lab equipment	5 Years		10,540			10,493
Furniture and fixtures	5 Years		235			235
Leasehold improvements	Shorter of lease term or estimated useful life		876			876
Assets not yet placed in service			354			114
Total			14,257			13,964
Less: Accumulated depreciation			(8,559	)		(7,990	)
Property and equipment, net		$	5,698		$	5,974

Depreciation expense on fixed assets totaled $569,000 and $535,000 for the first quarters of 2020 and 2019, respectively.

Significant Balance Sheet Accounts

3 Months Ended

Mar. 31, 2020

Balance Sheet Related Disclosures [Abstract]

Significant Balance Sheet Accounts

Note 6. Significant Balance Sheet Accounts

Other current assets consisted of the following:

	March 31,		December 31,
	2020		2019
	(in thousands)
Reagents and supplies	$	1,531	$	277
Contract assets		150		150
Prepaid expenses		1,211		1,288
Prepaid income taxes		46		46
Marketable securities interest receivable		354		478
Other receivable		32		16
Total	$	3,324	$	2,255

Reagents are used for DNA sequencing applications in the Company’s DNA sequencing equipment.

Reporting Segment and Geographic Information

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Reporting Segment and Geographic Information

Note 7. Reporting Segment and Geographic Information

The Company views its operations and manages its business in one reporting segment. Long-lived assets were primarily located in the United States as of March 31, 2020 and December 31, 2019 with an insignificant amount located in Canada. Revenue by region was as follows:

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Revenue:
United States	$	5,639	$	3,613
Foreign:
Canada		619		538
Other Countries		1,495		1,219
Total	$	7,753	$	5,370

Commitments and Contingencies

3 Months Ended

Mar. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 8. Commitments and Contingencies

Operating Leases

See Note 9, Leases, for further information.

FF Gene Biotech

See Note 14 for a description of the Company’s commitments related to its joint venture, FF Gene Biotech (as defined in Note 14).

Purchase Obligations

As of March 31, 2020, the Company had non-cancelable purchase obligations of $3.2 million for reagents and other supplies, of which, $2.7 million is payable within the next twelve months, and $469,000 is payable within the next twenty-four months.

Contingencies

From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

Leases

3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Leases

Note 9. Leases

The Company has various non-cancelable operating leases with varying terms through August 2023 primarily for office space. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease basis. The Company does not have any finance leases or leases with variable lease payments.

The determination of whether an arrangement contains a lease is made at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset.

The Company’s headquarters is located in Temple City, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), accredited by the College of American Pathologists (“CAP”) and licensed by the State of California Department of Public Health. Additional offices are located in El Monte, California and Atlanta, Georgia and are used for certain research and development, customer service, report generation and other administrative functions.

The Company adopted new accounting standard ASC 842, Leases, on January 1, 2019. Upon adoption, the Company recorded right-of-use (“ROU”) assets of $3.0 million and short-term and long-term lease liabilities of $384,000 and $2.6 million, respectively. The difference between the ROU asset and liability is due to the existing balance of deferred rent at the date of adoption. There was no impact to retained earnings upon adoption.

As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on information available at the commencement date in determining the discount rate used to calculate present value lease payment. The Company determined its incremental borrowing rate based on inquiries with its bank. The Company’s lease agreements do not contain any residual value guarantees, material restrictive covenants, bargain purchase options or asset retirement obligations. Lease expense for the Company’s operating leases is recognized on a straight-line basis over the lease term. The Company’s leases do not contain variable lease payments. The Company does not have any short-term leases and thus has excluded short-term costs from the table below. The Company did not enter into any new leases during the three months ended March 31, 2020.

The following was operating lease expense:

	Three months ended March 31,
	2020		2019
	(in thousands)
Operating lease cost	$	149	146

Supplemental cash flow information related to leases was the following:

	Three months ended March 31,
	2020		2019
	(in thousands)
Cash paid for amounts included in the measurement of lease liabilities	$	163	134
Noncash lease expense	$	108	100

Supplemental information related to leases was the following:

	March 31, 2020
Weighted average remaining lease term - operating leases	5.4 years
Weighted average discount rate - operating leases		6.25	%

The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:

	Operating Leases
	(in thousands)
Year Ending December 31,
2020 (remaining 9 months)	$	433
2021		591
2022		597
2023		567
2024		330
2025		317
Thereafter		215
Total lease payments		3,050
Less imputed interest		(476	)
Total	$	2,574

Equity-Based Compensation

3 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

Note 10. Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Operations as follows:

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Cost of revenue	$	231	$	142
Research and development		312		178
Selling and marketing		171		125
General and administrative		210		138
Total	$	924	$	583

Income Taxes

3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

Note 11. Income Taxes

Provision for income taxes consists of U.S. federal and state income taxes. A deferred tax liability is recognized for all taxable temporary differences, and a deferred tax asset is recognized for all deductible temporary differences, operating losses and tax credit carryforwards. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate for the full fiscal year ending December 31, 2020, which is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates, adjusted for discrete items recognized during the period. Certain significant or unusual items are separately recognized in the quarter during which they occur and can cause the effective tax rate to vary from quarter to quarter.

The Company’s effective tax rates were -2% and -1% for the three months ended March 31, 2020 and 2019, respectively. The change in effective tax rate for the three months ended March 31, 2020 and 2019 was primarily attributable to the full valuation allowance and certain minimum state income taxes.

Loss per Share

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Loss per Share

Note 12. Loss per Share

The following table presents the calculation of basic and diluted loss per share for the first quarters of 2020 and 2019:

	Three Months Ended March 31,
	2020			2019
	(in thousands, except per share data)
Net loss	$	(1,956	)	$	(1,908	)
Weighted-average common shares—outstanding, basic		21,566			18,228
Weighted-average common shares—outstanding, diluted		21,566			18,228
Net loss per common share, basic	$	(0.09	)	$	(0.10	)
Net loss per common share, diluted	$	(0.09	)	$	(0.10	)

The following securities have been excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive:

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Options		307		400
RSUs		1,367		1,068

The anti-dilutive shares described above were calculated using the treasury stock method. During the first quarters of 2020 and 2019, the Company had outstanding stock options and RSUs that were excluded from the weighted-average share calculation due to the Company’s net loss position.

Related Party

3 Months Ended

Mar. 31, 2020

Related Party

Note 13. Related Party

Dr. Yun Yen, who is a member of the Company’s Board of Directors and a stockholder, serves as the President and Chairman of the Board for the Sino-American Cancer Foundation (the “Foundation”) and served as the President for the Taipei Medical University (the “University”), from August 1, 2011 through July 31, 2016.

From time to time, the Company performs research testing services, on an arms-length basis, for the Foundation. The Company recognized zero in revenue during the first quarters of 2020 and 2019, as consideration for such services. Additionally, the Company subleased certain of its headquarters facilities to the Foundation prior to April 2019. The Company recognized $8,000 in the first quarter of 2019, as consideration for such sublease. As of March 31, 2020, and December 31, 2019, an insignificant amount was owed to the Company by the Foundation in connection with these relationships.

From time to time, the Company performs genetic sequencing services, on an arms-length basis, for the University. The Company recognized $49,000 and $13,000 as consideration for such services in the first quarters of 2020 and 2019, respectively. As of March 31, 2020, and December 31, 2019, $49,000 and $39,000, respectively, was owed to the Company by the University in connection with this relationship.

As more fully described in Note 14, in April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into a cooperation agreement (the “JV Agreement”) with Xilong Scientific Co., Ltd. (“Xilong Scientific”) and Fuzhou Jinqiang Investment Partnership (LP) (“FJIP”) to form a joint venture under the laws of the People’s Republic of China (“PRC”) called Fujian Fujun Gene Biotech Co., Ltd. (“FF Gene Biotech”). Xilong Scientific is an affiliate of Xi Long USA, Inc., a large stockholder of the Company that, as of March 31, 2020, owned 9.3% of the outstanding shares of the Company’s common stock, and FJIP is owned by key management of FF Gene Biotech, including Dr. Han Lin Gao, the Chief Scientific Officer and a large stockholder of the Company and the owner of approximately 25% of FJIP.

Fulgent Pharma, LLC, or Fulgent Pharma, a former subsidiary of one of the Company's subsidiaries utilizes space in the facility at which the Company’s laboratory and corporate headquarters are located. Fulgent Pharma reimburses the Company for the portion of the rent the Company pays that is attributable to the space it uses, which amounts are not significant. As of March 31, 2020, and December 31, 2019, $25,000 and $26,000, respectively, was due from Fulgent Pharma as a result of this arrangement, which is recorded in Other receivable in Other current assets in the accompanying Condensed Consolidated Balance Sheets.

Equity Method Investments

3 Months Ended

Mar. 31, 2020

Equity Method Investments And Joint Ventures [Abstract]

Equity Method Investments

Note 14. Equity Method Investments

In April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into the JV Agreement with Xilong Scientific and FJIP to form FF Gene Biotech, a joint venture formed under the laws of the PRC to offer genetic testing services to customers in the PRC. Pursuant to the terms of the JV Agreement, the Company has agreed to contribute to FF Gene Biotech genetic sequencing and other equipment with a total cost of 60,000,000 renminbi (“RMB”) over a five-year period for a 30% ownership interest in FF Gene Biotech, previously three-year per original agreement and amended in April 2019, Xilong Scientific has agreed to contribute to FF Gene Biotech 102,000,000 RMB over a five-year period for a 51% ownership interest in the FF Gene Biotech, previously three-year per original agreement and amended in April 2019, and FJIP has agreed to contribute to FF Gene Biotech 19,000,000 RMB over a ten-year period for a 19% ownership interest in FF Gene Biotech, previously five-year per original agreement and amended in April 2019. The Company’s maximum exposure to fund losses of FF Gene Biotech as a result of its minority ownership of this entity is equal to its contribution obligation under the JV Agreement as described above. As of March 31, 2020, 39,300,000 RMB (or approximately $5.5 million U.S. dollars) remains to be contributed to the investee under the terms of the JV agreement. To date, the Company has purchased and contributed equipment with an aggregate fair value of $3.1 million pursuant to its contribution commitment under the JV Agreement. The Company accounted for this contribution in accordance with ASC 845, Nonmonetary Transactions, and recorded an investment based on the fair value of the contributed equipment, which is the same as carryover basis.

The Company concluded FF Gene Biotech is a variable interest entity as FF Gene Biotech lacks sufficient capital to operate independently. The Company concluded that it alone does not have the power to direct the most significant activities of FF Gene Biotech and therefore is not the primary beneficiary of the entity. Judgment regarding the level of influence over FF Gene Biotech includes consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions.

The Company accounts for its 30% interest in FF Gene Biotech using the equity method of accounting. The Company recorded its proportionate share of the losses of FF Gene Biotech in the three months ended March 31, 2020 in the accompanying Condensed Consolidated Statements of Operations, and recorded its contribution to date, net of its proportionate share in the accumulated losses of FF Gene Biotech, in the accompanying Condensed Consolidated Balance Sheet as of March 31, 2020.

Equity method investments as of March 31, 2020 and December 31, 2019 consisted of the following:

	March 31, 2020					December 31, 2019
	Carrying Value		Ownership Percentage			Carrying Value		Ownership Percentage
	(in thousands)
FF Gene Biotech	$	623		30	%	$	872		30	%
Total equity method investments	$	623		30	%	$	872		30	%

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Use of Estimates

Foreign Currency Translation and Foreign Currency Transactions

Leases

Concentration of Customers

Revenue from Contracts with Customers

Disaggregation of Revenue

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Genetic Testing Services by payor
Institutional	$	7,478	$	5,119
Patient		141		102
Insurance		134		149
Total Revenue	$	7,753	$	5,370

Contract Balances

Transaction Price Allocated to Future Performance Obligations

The Company does not have material future obligations associated with genetic testing services that extend beyond one year.

Recent Accounting Pronouncements

ASU No. 2016-13

ASU No. 2018-15

ASU No. 2019-12

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2020

Accounting Standards Update 2014-09

Summary of Revenue from Contracts with Customers by Payor Type

The following table summarizes revenue from contracts with customers by payor type for the first quarters of 2020 and 2019.

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Genetic Testing Services by payor
Institutional	$	7,478	$	5,119
Patient		141		102
Insurance		134		149
Total Revenue	$	7,753	$	5,370

Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2020

Investments Debt And Equity Securities [Abstract]

Summary of Marketable Securities

The Company’s marketable securities consisted of the following:

	March 31, 2020
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	3,943		$	—	$	—		$	3,943
Corporate debt securities		18,048			31		(51	)		18,028
Less: Cash equivalents		(3,943	)		—		—			(3,943	)
Total short-term marketable securities		18,048			31		(51	)		18,028
Long-term
Corporate debt securities		42,484			125		(318	)		42,291
U.S. government agency securities		1,000			3		—			1,003
Total long-term marketable securities		43,484			128		(318	)		43,294
Total marketable securities	$	61,532		$	159	$	(369	)	$	61,322

	December 31, 2019
	Amortized Cost Basis			Unrealized Gains		Unrealized Losses			Aggregate Fair Value
	(in thousands)
Marketable securities:
Short-term
Money market accounts	$	4,700		$	—	$	—		$	4,700
Corporate debt securities		17,962			43		(2	)		18,003
Less: Cash equivalents		(6,399	)		—		—			(6,399	)
Total short-term marketable securities		16,263			43		(2	)		16,304
Corporate debt securities		41,861			116		(30	)		41,947
Total long-term marketable securities		41,861			116		(30	)		41,947
Total marketable securities	$	58,124		$	159	$	(32	)	$	58,251

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

	March 31, 2020
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	60,319	$	—	$	60,319	$	—
U.S. government agency securities		1,003		—		1,003		—
Money market accounts		3,943		3,943		—		—
Total marketable securities	$	65,265	$	3,943	$	61,322	$	—

	December 31, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Marketable securities and cash equivalents:
Corporate debt securities	$	59,950	$	—	$	59,950	$	—
Money market accounts		4,700		4,700		—		—
Total marketable securities and cash equivalents	$	64,650	$	4,700	$	59,950	$	—

Fixed Assets (Tables)

3 Months Ended

Mar. 31, 2020

Property Plant And Equipment [Abstract]

Major Classes of Fixed Assets

Major classes of fixed assets consisted of the following:

		March 31,			December 31,
	Useful Lives	2020			2019
		(in thousands)
Computer hardware	3 Years	$	1,711		$	1,705
Computer software	3 Years		541			541
Medical lab equipment	5 Years		10,540			10,493
Furniture and fixtures	5 Years		235			235
Leasehold improvements	Shorter of lease term or estimated useful life		876			876
Assets not yet placed in service			354			114
Total			14,257			13,964
Less: Accumulated depreciation			(8,559	)		(7,990	)
Property and equipment, net		$	5,698		$	5,974

Significant Balance Sheet Accounts (Tables)

3 Months Ended

Mar. 31, 2020

Balance Sheet Related Disclosures [Abstract]

Schedule of Other Current Assets

Other current assets consisted of the following:

	March 31,		December 31,
	2020		2019
	(in thousands)
Reagents and supplies	$	1,531	$	277
Contract assets		150		150
Prepaid expenses		1,211		1,288
Prepaid income taxes		46		46
Marketable securities interest receivable		354		478
Other receivable		32		16
Total	$	3,324	$	2,255

Reporting Segment and Geographic Information (Tables)

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Summary of Revenue by Geographic Region

Revenue by region was as follows:

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Revenue:
United States	$	5,639	$	3,613
Foreign:
Canada		619		538
Other Countries		1,495		1,219
Total	$	7,753	$	5,370

Leases (Tables)

3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Schedule of Operating Lease Expense

The following was operating lease expense:

	Three months ended March 31,
	2020		2019
	(in thousands)
Operating lease cost	$	149	146

Schedule of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases was the following:

	Three months ended March 31,
	2020		2019
	(in thousands)
Cash paid for amounts included in the measurement of lease liabilities	$	163	134
Noncash lease expense	$	108	100

Schedule of Supplemental Information Related To Leases

Supplemental information related to leases was the following:

	March 31, 2020
Weighted average remaining lease term - operating leases	5.4 years
Weighted average discount rate - operating leases		6.25	%

Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis

The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:

	Operating Leases
	(in thousands)
Year Ending December 31,
2020 (remaining 9 months)	$	433
2021		591
2022		597
2023		567
2024		330
2025		317
Thereafter		215
Total lease payments		3,050
Less imputed interest		(476	)
Total	$	2,574

Equity-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Operations as follows:

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Cost of revenue	$	231	$	142
Research and development		312		178
Selling and marketing		171		125
General and administrative		210		138
Total	$	924	$	583

Loss per Share (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Reconciliation of Basic and Diluted Loss per Share Computations

The following table presents the calculation of basic and diluted loss per share for the first quarters of 2020 and 2019:

	Three Months Ended March 31,
	2020			2019
	(in thousands, except per share data)
Net loss	$	(1,956	)	$	(1,908	)
Weighted-average common shares—outstanding, basic		21,566			18,228
Weighted-average common shares—outstanding, diluted		21,566			18,228
Net loss per common share, basic	$	(0.09	)	$	(0.10	)
Net loss per common share, diluted	$	(0.09	)	$	(0.10	)

Anti-dilutive Securities Excluded from Calculation of Diluted Loss per Share

The following securities have been excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive:

	Three Months Ended March 31,
	2020		2019
	(in thousands)
Options		307		400
RSUs		1,367		1,068

Equity Method Investments (Tables)

3 Months Ended

Mar. 31, 2020

Equity Method Investments And Joint Ventures [Abstract]

Schedule of Equity Method Investments

Equity method investments as of March 31, 2020 and December 31, 2019 consisted of the following:

	March 31, 2020					December 31, 2019
	Carrying Value		Ownership Percentage			Carrying Value		Ownership Percentage
	(in thousands)
FF Gene Biotech	$	623		30	%	$	872		30	%
Total equity method investments	$	623		30	%	$	872		30	%

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2020 USD ($) Customer	Mar. 31, 2019 USD ($) Customer	Dec. 31, 2019 USD ($) Customer
Summary Of Significant Accounting Policies [Line Items]
Foreign currency, losses from remeasurements	$ 85,000
Receivables from contract with customers	6,371,000		$ 6,555,000
Contract liability	444,000		365,000
Contract with customer liability, revenue recognized	242,000	$ 33,000
Practical expedient not to disclose amount of transaction price allocated to unsatisfied performance obligations		true
Other Current Assets
Summary Of Significant Accounting Policies [Line Items]
Contract assets from contract with customers	$ 150,000		$ 150,000
Customer Concentration Risk \| Revenue
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer		2
Customer Concentration Risk \| Revenue \| Customer One
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage		20.00%
Customer Concentration Risk \| Revenue \| Customer Two
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage		11.00%
Customer Concentration Risk \| Revenue \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer	0
Concentration risk, percentage	10.00%
Customer Concentration Risk \| Accounts Receivable \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Number of customers \| Customer	0		0
Concentration risk, percentage	10.00%		10.00%

Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	$ 7,753	$ 5,370
Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Type of Revenue [Extensible List]	flgt:GeneticTestingServicesMember	flgt:GeneticTestingServicesMember
Revenue from contracts with customers by payor type	$ 7,753	$ 5,370
Clinical Institutional Contracts \| Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	7,478	5,119
Clinical Patient Contracts \| Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	141	102
Clinical Insurance Contracts \| Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	$ 134	$ 149

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	$ 61,532	$ 58,124
Marketable securities, Unrealized Gains	159	159
Marketable securities, Unrealized Losses	(369)	(32)
Marketable securities, Aggregate Fair Value	61,322	58,251
Cash and cash equivalents	9,302	11,965
Less: Cash equivalents	(3,943)	(6,399)
Short-Term Marketable Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	18,048	16,263
Marketable securities, Unrealized Gains	31	43
Marketable securities, Unrealized Losses	(51)	(2)
Marketable securities, Aggregate Fair Value	18,028	16,304
Short-Term Marketable Securities \| Money Market Accounts
Schedule Of Available For Sale Securities [Line Items]
Cash and cash equivalents	3,943	4,700
Cash and cash equivalents fair value disclosure	3,943	4,700
Short-Term Marketable Securities \| Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	18,048	17,962
Marketable securities, Unrealized Gains	31	43
Marketable securities, Unrealized Losses	(51)	(2)
Marketable securities, Aggregate Fair Value	18,028	18,003
Long-Term Marketable Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	43,484	41,861
Marketable securities, Unrealized Gains	128	116
Marketable securities, Unrealized Losses	(318)	(30)
Marketable securities, Aggregate Fair Value	43,294	41,947
Long-Term Marketable Securities \| U.S. Government Agency Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	1,000
Marketable securities, Unrealized Gains	3
Marketable securities, Aggregate Fair Value	1,003
Long-Term Marketable Securities \| Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	42,484	41,861
Marketable securities, Unrealized Gains	125	116
Marketable securities, Unrealized Losses	(318)	(30)
Marketable securities, Aggregate Fair Value	$ 42,291	$ 41,947

Marketable Securities - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]
Gross unrealized loss	$ 369,000	$ 32,000

Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	$ 61,322	$ 58,251
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	65,265	64,650
Fair Value Measurements Recurring \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	3,943	4,700
Fair Value Measurements Recurring \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	61,322	59,950
Fair Value Measurements Recurring \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	0	0
Fair Value Measurements Recurring \| Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	60,319	59,950
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	0	0
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	60,319	59,950
Fair Value Measurements Recurring \| Corporate Debt Securities \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	0	0
Fair Value Measurements Recurring \| U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	1,003
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	0
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	1,003
Fair Value Measurements Recurring \| U.S. Government Agency Securities \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	0
Fair Value Measurements Recurring \| Money Market Accounts
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	3,943	4,700
Fair Value Measurements Recurring \| Money Market Accounts \| Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	3,943	4,700
Fair Value Measurements Recurring \| Money Market Accounts \| Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	0	0
Fair Value Measurements Recurring \| Money Market Accounts \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	$ 0	$ 0

Fair Value Measurements - Additional Information (Details)	3 Months Ended
	Mar. 31, 2020 USD ($)
Fair Value Disclosures [Abstract]
Fair value asset, investments measured using unobservable inputs	$ 0
Fair value assets, transfers between levels, amount	0
Unrealized losses for securities in an unrealized loss position for more than 12 months	0
Other-than-temporary impairment losses related to marketable securities	$ 0

Fixed Assets - Major Classes of Fixed Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 14,257	$ 13,964
Less: Accumulated depreciation	(8,559)	(7,990)
Fixed assets, net	5,698	5,974
Computer Hardware
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 1,711	1,705
Useful life in years	3 years
Computer Software
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 541	541
Useful life in years	3 years
Medical Lab Equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 10,540	10,493
Useful life in years	5 years
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 235	235
Useful life in years	5 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 876	876
Useful life in years	Shorter of lease term or estimated useful life
Assets Not Yet Placed in Service
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 354	$ 114

Fixed Assets - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property Plant And Equipment [Abstract]
Depreciation expense on fixed assets	$ 569,000	$ 535,000

Significant Balance Sheet Acconts - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Reagents and supplies	$ 1,531	$ 277
Contract assets	150	150
Prepaid expenses	1,211	1,288
Prepaid income taxes	46	46
Marketable securities interest receivable	354	478
Other receivable	32	16
Total	$ 3,324	$ 2,255

Reporting Segment and Geographical Information - Additional Information (Details)	3 Months Ended
	Mar. 31, 2020 Segment
Segment Reporting [Abstract]
Number of reporting segments	1

Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 7,753	$ 5,370
United States
Segment Reporting Information [Line Items]
Revenue	5,639	3,613
Canada
Segment Reporting Information [Line Items]
Revenue	619	538
Other Countries
Segment Reporting Information [Line Items]
Revenue	$ 1,495	$ 1,219

Commitments and Contingencies - Additional Information (Details) - Reagents and Other Supplies	Mar. 31, 2020 USD ($)
Commitments And Contingencies [Line Items]
Non-cancelable purchase obligations	$ 3,200,000
Non-cancelable purchase obligations, payable within next twelve months	2,700,000
Non-cancelable purchase obligations, payable within next twenty-four months	$ 469,000

Leases - Additional Information (Details) - USD ($)	3 Months Ended
Leases - Additional Information (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Jan. 01, 2019
Lessee Lease Description [Line Items]
Operating leases term of expiration	2023-08
Operating leases, renewal term	3 years
Long-term ROU assets	$ 2,525,000	$ 2,633,000	$ 3,000,000
Short-term lease liabilities	431,000	420,000	384,000
Long-term lease liabilities	2,143,000	$ 2,256,000	$ 2,600,000
Accounting Standards Update 2016-02
Lessee Lease Description [Line Items]
Impact to retained earnings upon adoption of new accounting standard	$ 0

Leases - Schedule of Operating Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating lease cost	$ 149	$ 146

Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 163	$ 134
Noncash lease expense	$ 108	$ 100

Leases - Schedule of Supplemental Information Related to Leases (Details)	Mar. 31, 2020
Leases [Abstract]
Weighted average remaining lease term - operating leases	5 years 4 months 24 days
Weighted average discount rate - operating leases	6.25%

Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details) $ in Thousands	Mar. 31, 2020 USD ($)
Leases [Abstract]
2020 (remaining 9 months)	$ 433
2021	591
2022	597
2023	567
2024	330
2025	317
Thereafter	215
Total lease payments	3,050
Less imputed interest	(476)
Total	$ 2,574

Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 924	$ 583
Cost of Revenue
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	231	142
Research and Development
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	312	178
Selling and Marketing
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	171	125
General and Administrative
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 210	$ 138

Income Taxes - Additional Information (Details)	3 Months Ended
Income Taxes - Additional Information (Details)	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Effective income tax rate	(2.00%)	(1.00%)

Loss per Share - Reconciliation of Basic and Diluted Loss per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net loss	$ (1,956)	$ (1,908)
Weighted-average common shares—outstanding, basic	21,566	18,228
Weighted-average common shares—outstanding, diluted	21,566	18,228
Net loss per common share, basic	$ (0.09)	$ (0.10)
Net loss per common share, diluted	$ (0.09)	$ (0.10)

- Definition

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227

+ Details

- Definition

The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Loss per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Loss per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted loss per share	307	400
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted loss per share	1,367	1,068

Related Party - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Apr. 30, 2017
Related Party Transaction [Line Items]
Ownership percentage	30.00%		30.00%
Xilong Scientific
Related Party Transaction [Line Items]
Ownership percentage of common stock outstanding shares	9.30%
Foundation
Related Party Transaction [Line Items]
Revenue from sublease		$ 8,000
Foundation \| Research Testing Services
Related Party Transaction [Line Items]
Revenue from related parties	$ 0	0
University \| Genetic Sequencing Services
Related Party Transaction [Line Items]
Revenue from related parties	49,000	$ 13,000
Due from related parties	$ 49,000		$ 39,000
FF Gene Biotech \| FJIP
Related Party Transaction [Line Items]
Ownership percentage				19.00%
FF Gene Biotech \| Dr. Han Lin Gao \| FJIP
Related Party Transaction [Line Items]
Ownership percentage	25.00%
Fulgent Pharma, LLC
Related Party Transaction [Line Items]
Due from related parties	$ 25,000		$ 26,000

Equity Method Investments - Additional Information (Details) $ in Millions	1 Months Ended	3 Months Ended
	Apr. 30, 2017 CNY (¥)	Mar. 31, 2020 USD ($)	Mar. 31, 2020 CNY (¥)	Dec. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Ownership interest to be made in joint venture		30.00%	30.00%	30.00%
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture	¥ 60,000,000
Contribution period in joint venture	5 years
Ownership interest to be made in joint venture	30.00%	30.00%	30.00%	30.00%
Contributions remain for joint venture		$ 5.5	¥ 39,300,000
FF Gene Biotech \| Equipment
Schedule Of Equity Method Investments [Line Items]
Contributions made to joint venture \| $		$ 3.1
Xilong Scientific \| FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture	¥ 102,000,000
Contribution period in joint venture	5 years
Ownership interest to be made in joint venture	51.00%
FJIP \| FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture	¥ 19,000,000
Contribution period in joint venture	10 years
Ownership interest to be made in joint venture	19.00%

Equity Method Investments - Schedule of Equity Method Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Apr. 30, 2017
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 623	$ 872
Ownership percentage	30.00%	30.00%
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 623	$ 872
Ownership percentage	30.00%	30.00%	30.00%